These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 9205777

  • 1. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 5th communication: hemodynamic effects of valsartan in dog heart failure models.
    Yamamoto S, Hayashi N, Kometani M, Nakao K.
    Arzneimittelforschung; 1997 May; 47(5):630-4. PubMed ID: 9205777
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
    Hayashi N, Fujimura Y, Yamamoto S, Kometani M, Nakao K.
    Arzneimittelforschung; 1997 May; 47(5):625-9. PubMed ID: 9205776
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: hemodynamic effects of valsartan in rats and dogs.
    Hayashi N, Yamamoto S, Kometani M, Nakao K.
    Arzneimittelforschung; 1997 May; 47(5):620-5. PubMed ID: 9205775
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
    Kometani M, Hayashi N, Yamamoto S, Nakao K, Inukai T.
    Arzneimittelforschung; 1997 May; 47(5):613-9. PubMed ID: 9205774
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
    Yamamoto S, Hayashi N, Kometani M, Nakao K, Inukai T.
    Arzneimittelforschung; 1997 May; 47(5):604-12. PubMed ID: 9205773
    [Abstract] [Full Text] [Related]

  • 6. Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors.
    Rehman A, Rahman AR, Rasool AH.
    J Hum Hypertens; 2002 Apr; 16(4):261-6. PubMed ID: 11967720
    [Abstract] [Full Text] [Related]

  • 7. Haemodynamic effects of a selective adenosine A2A receptor agonist, CGS 21680, in chronic heart failure in anaesthetized rats.
    Nekooeian AA, Tabrizchi R.
    Br J Pharmacol; 1998 Oct; 125(4):651-8. PubMed ID: 9831898
    [Abstract] [Full Text] [Related]

  • 8. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
    Spinale FG, de Gasparo M, Whitebread S, Hebbar L, Clair MJ, Melton DM, Krombach RS, Mukherjee R, Iannini JP, O SJ.
    Circulation; 1997 Oct 07; 96(7):2385-96. PubMed ID: 9337215
    [Abstract] [Full Text] [Related]

  • 9. Effects of CGS 21680, a selective A2A adenosine receptor agonist, on cardiac output and vascular resistance in acute heart failure in the anaesthetized rat.
    Nekooeian AA, Tabrizchi R.
    Br J Pharmacol; 1998 Apr 07; 123(8):1666-72. PubMed ID: 9605574
    [Abstract] [Full Text] [Related]

  • 10. Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation.
    Thai H, Guarraia D, Johnson N, Goldman S, Gaballa MA.
    J Cardiovasc Pharmacol; 2007 Dec 07; 50(6):703-7. PubMed ID: 18091589
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin II type 1 receptor blocker, valsartan, prevented cardiac fibrosis in rat cardiomyopathy after autoimmune myocarditis.
    Tachikawa H, Kodama M, Hui L, Yoshida T, Hayashi M, Abe S, Kashimura T, Kato K, Hanawa H, Watanabe K, Nakazawa M, Aizawa Y.
    J Cardiovasc Pharmacol; 2003 Jan 07; 41 Suppl 1():S105-10. PubMed ID: 12688405
    [Abstract] [Full Text] [Related]

  • 12. AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns.
    Clair MJ, Krombach RS, Hendrick JW, Houck WV, Hebbar L, Kribbs SB, Rios G, Whitebread S, Mukherjee R, de Gasparo M, Spinale FG.
    J Card Fail; 1998 Dec 07; 4(4):311-23. PubMed ID: 9924853
    [Abstract] [Full Text] [Related]

  • 13. Acute hemodynamic effects of drugs acting on the renin-angiotensin system in acute heart failure.
    Nekooeian AA, Ogilvie RI, Zborowska-Sluis D.
    Can J Cardiol; 1995 Jan 07; 11(1):59-64. PubMed ID: 7850666
    [Abstract] [Full Text] [Related]

  • 14. Valsartan restores sarcoplasmic reticulum function with no appreciable effect on resting cardiac function in pacing-induced heart failure.
    Okuda S, Yano M, Doi M, Oda T, Tokuhisa T, Kohno M, Kobayashi S, Yamamoto T, Ohkusa T, Matsuzaki M.
    Circulation; 2004 Feb 24; 109(7):911-9. PubMed ID: 14757694
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological profile of nicardipine hydrochloride in anesthetized dogs with acute heart failure. Part 1: Hemodynamic effects in normal dogs and dogs with acute heart failure.
    Saitoh C, Momose K, Tanaka H, Sato S, Taguchi K, Saitoh M, Maehara J, Asano M, Usuda S.
    Arzneimittelforschung; 1998 Feb 24; 48(2):125-32. PubMed ID: 9541721
    [Abstract] [Full Text] [Related]

  • 16. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K, Minatoguchi S, Ito Y, Hukunishi M, Matsuno Y, Kakami M, Kawasaki M, Nishigaki K, Takemura G, Fujiwara H.
    Hypertens Res; 2007 Apr 24; 30(4):307-13. PubMed ID: 17541209
    [Abstract] [Full Text] [Related]

  • 17. Combined angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on survival and cardiac remodeling in chronic heart failure in rats.
    Richer C, Fornes P, Domergue V, De Gasparo M, Giudicelli JF.
    J Card Fail; 2001 Sep 24; 7(3):269-76. PubMed ID: 11561229
    [Abstract] [Full Text] [Related]

  • 18. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
    Gottdiener JS.
    Circulation; 1999 Aug 10; 100(6):685-6. PubMed ID: 10490345
    [No Abstract] [Full Text] [Related]

  • 19. Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects.
    Latif F, Tandon S, Obeleniene R, Hankins SR, Berlowitz MS, Ennezat PV, Le Jemtel TH.
    J Card Fail; 2001 Sep 10; 7(3):265-8. PubMed ID: 11561228
    [Abstract] [Full Text] [Related]

  • 20. [Lowering of blood pressure, blood pressure amplitude and heart rate by treatment with valsartan or valsartan/hydrochlorothiazide. Results of an open observation study of 11,447 hypertensives].
    Weisser B, Vetter H, Mengden T.
    Dtsch Med Wochenschr; 2003 Mar 14; 128(11):541-4. PubMed ID: 12635025
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.